Larrue et al.31 showed that FLT3-ITD+ primary AML samples are more sensitive than wild-type samples to proteasome inhibition by bortezomib, and that this sensitivity correlates to FLT3-ITD allele burden. This evidence concerns the gene FLT3 and acute myeloid leukemia.